Services in support of the scleroderma research program, congressionally directed medical research programs
Ended Awarded Last action
- Contract number
- W81XWH20F0311
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $204,188
Award facts
- Opportunity
-
- W81XWH17R0036 Solicitation number
- Meeting, Scientific and Administrative Support Services (MSASS), Request for Proposal (RFP) Award Notice · Posted Apr 12, 2017
- Meeting, Scientific and Administrative Support Services Award Notice · Posted Mar 22, 2017
- Contract value 77% obligated
-
- $204,187.84 Current, with exercised options
- $264,187.84 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Two Step
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$60,000 | |
| Exercise an Option | $138,703 | |
| Original award | $125,485 |
About this award
Leidos, Inc., through its Leidos Services Operating Segment (doing business as SAIC), was awarded a delivery order valued at $264,187.84 to provide support services for the Scleroderma Research Program under the Congressionally Directed Medical Research Programs (CDMRP). This cost-plus-fixed-fee delivery order, issued by the Defense Health Agency (Medical Command) on August 31, 2020, with an ultimate completion date of August 30, 2022, supports administrative and technical services for scleroderma research initiatives. The work is to be performed in Frederick, Maryland, and no set-aside designation was utilized for this award. Leidos is a major federal contractor with extensive experience delivering medical research support services across multiple disease areas and research programs within the Department of Defense.
The CDMRP, administered through the Department of Defense, is congressionally authorized to fund peer-reviewed, innovative research in specific medical areas designated by Congress. Leidos' award reflects the company's established role as a critical support contractor for federal medical research initiatives, building on its broader portfolio of defense health research contracts valued in the hundreds of millions of dollars with the Naval Health Research Center and Defense Health Agency. This delivery order represents continued engagement in supporting the nation's investment in scleroderma research, a connective tissue disorder affecting thousands of Americans, through comprehensive program administration and technical support services.
Quick answers
Who was awarded contract W81XWH20F0311?
W81XWH20F0311 was awarded to Leidos, Inc. by Medical Command (Department of the Army) on August 31, 2020.
How much is contract W81XWH20F0311 worth?
The government has obligated $204,188 on W81XWH20F0311. Its potential value, with all options, is $264,188.
Is contract W81XWH20F0311 an order under another contract?
Yes. W81XWH20F0311 is a delivery order under W81XWH17D0025, an indefinite delivery contract.
Was contract W81XWH20F0311 competed?
The extent of competition for W81XWH20F0311 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award